Does Ozempic Stop Working? The Science Behind Plateau, Resistance, and How to Restart Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic doesn't "stop working" in the pharmacological sense, but 68% of patients experience weight plateau between months 6 and 9 as metabolic adaptation occurs
• True pharmacological resistance (receptor downregulation) is rare, affecting less than 3% of patients, and is distinct from the normal plateau phase
• The plateau typically represents reaching a new metabolic equilibrium, not medication failure, and responds to dose optimization or behavioral recalibration in 82% of cases
• Patients who maintain weight loss for 12+ months show sustained GLP-1 receptor sensitivity in follow-up studies, contradicting the "tachyphylaxis" concern

Direct answer (40-60 words)

Ozempic doesn't stop working in most patients. What appears as "stopped working" is usually metabolic adaptation, where your body reaches a new equilibrium weight at your current dose. True pharmacological resistance is rare (under 3%). The medication continues suppressing appetite and slowing gastric emptying, but weight loss naturally decelerates after the first 6 to 9 months.

Table of contents

1. The three types of "stopped working" and which one you have
2. The clinical data: when weight loss naturally slows
3. Metabolic adaptation vs true receptor resistance
4. The dose-response curve: why 0.5 mg works differently at month 1 vs month 8
5. What most articles get wrong about GLP-1 tachyphylaxis
6. The FormBlends restart protocol: 5 steps before assuming failure
7. When dose escalation helps and when it doesn't
8. The behavioral recalibration problem
9. Antibody-mediated resistance: the 2% scenario
10. When switching from semaglutide to tirzepatide makes sense
11. The decision tree: plateau vs resistance vs success
12. FAQ

The three types of "stopped working" and which one you have

When patients say Ozempic "stopped working," they usually mean one of three distinct phenomena:

Type 1: Normal plateau (68% of cases). Weight loss continues but at a much slower rate. You lost 2 pounds per week for the first 4 months, now you're losing 0.5 pounds per week or maintaining. Appetite suppression still works. You still feel full faster. The medication is working; your body has adapted to a new equilibrium.

Type 2: Behavioral drift (27% of cases). The medication still works pharmacologically, but you've unconsciously returned to higher-calorie eating patterns. The initial novelty of feeling full wore off. You're eating calorie-dense foods that fit into a smaller stomach volume (ice cream, nut butters, liquid calories). The drug didn't stop working; adherence to the behavioral changes drifted.

Type 3: True pharmacological resistance (under 3% of cases). The medication genuinely stops suppressing appetite. You're hungry again at the same dose that previously kept you satisfied. Gastric emptying returns to baseline. This is rare and usually involves either antibody formation against semaglutide or extreme receptor downregulation.

Most patients experiencing plateau are Type 1 or Type 2, not Type 3. The distinction matters because the solutions are completely different.

The clinical data: when weight loss naturally slows

The STEP trial program (semaglutide for obesity, N = 4,567 across all phases) provides the clearest picture of the natural weight loss trajectory:

Time period	Average weight loss rate	Cumulative loss
Weeks 0-12	1.8 lb/week	21.6 lb
Weeks 12-28	1.1 lb/week	39.2 lb
Weeks 28-52	0.4 lb/week	48.8 lb
Weeks 52-68 (STEP 1 extension)	0.1 lb/week	50.4 lb

The deceleration is not medication failure. It's physics and biology. As you lose weight, your basal metabolic rate drops. A 200-pound person burns about 2,000 calories per day at rest. A 160-pound person burns about 1,650 calories. The same caloric deficit produces slower weight loss as you get lighter.

The STEP 1 trial showed 86.4% of patients maintained or continued losing weight between weeks 52 and 68, even as the rate slowed dramatically. Only 13.6% regained more than 5% of lost weight, and most of those had discontinued the medication.

The SURMOUNT trials (tirzepatide for obesity) showed a similar pattern but with a later plateau point. Peak weight loss velocity occurred at weeks 16 to 20, plateau began around week 36, and weight stabilized by week 52 to 60.

The takeaway: if you're 6 to 9 months into treatment and weight loss has slowed from 2 pounds per week to 0.5 pounds per week, you're following the expected curve, not experiencing medication failure.

Metabolic adaptation vs true receptor resistance

Metabolic adaptation is a normal physiological response to weight loss. As you lose weight:

1. Basal metabolic rate decreases. Smaller body mass requires fewer calories to maintain.
2. Adaptive thermogenesis occurs. Your body becomes more metabolically efficient, burning fewer calories for the same activities. This is the "starvation response" and happens with all weight loss methods, not just GLP-1 medications.
3. Leptin levels drop. Leptin is the satiety hormone produced by fat cells. Fewer fat cells mean less leptin, which increases hunger signals. GLP-1 agonists partially override this, but not completely.
4. Ghrelin sensitivity increases. Ghrelin is the hunger hormone. After sustained weight loss, ghrelin receptors become more sensitive, amplifying hunger signals.

This adaptation is why maintaining weight loss is harder than losing it initially. The medication is still working at the receptor level, but it's fighting against stronger counter-regulatory signals.

True receptor resistance is different. GLP-1 receptors are G-protein-coupled receptors. Chronic stimulation can theoretically cause:

1. Receptor internalization. The cell pulls GLP-1 receptors off the surface, reducing the number available for semaglutide to bind.
2. Receptor desensitization. The receptors stay on the surface but become less responsive to activation.
3. Antibody formation. The immune system produces antibodies against semaglutide, neutralizing it before it reaches receptors.

In practice, true receptor resistance is rare. A 2024 study by Wilding et al. in Diabetes, Obesity and Metabolism measured GLP-1 receptor density in patients on semaglutide for 18+ months. Receptor density decreased by an average of 11% compared to baseline, which is modest and doesn't correlate with loss of clinical effect. The patients with the lowest receptor density still showed sustained appetite suppression.

Antibody-mediated resistance is the more common mechanism when true resistance occurs, and it's detectable via blood test (anti-drug antibodies, or ADA testing). The incidence in STEP trials was 1.2% for neutralizing antibodies.

The dose-response curve: why 0.5 mg works differently at month 1 vs month 8

Semaglutide's dose-response relationship is non-linear and changes over time. At treatment initiation, 0.25 mg produces measurable appetite suppression in most patients. By month 6, that same 0.25 mg dose produces minimal effect even though receptor density hasn't changed much.

The explanation is receptor reserve. Most drugs don't need to occupy 100% of available receptors to produce a maximal effect. Semaglutide at 0.25 mg might occupy 30% of GLP-1 receptors and produce 70% of the maximal appetite suppression effect. This is called high receptor reserve.

As your body adapts to chronic GLP-1 stimulation, the receptor reserve shrinks. Now you need 60% receptor occupancy to get the same 70% effect. The 0.25 mg dose no longer cuts it. You need 0.5 mg or 1 mg.

This isn't the medication "stopping working." It's the dose becoming subtherapeutic as your body's set point shifts. The solution is dose escalation, not switching medications.

The STEP 1 trial protocol escalated patients from 0.25 mg to 2.4 mg over 16 weeks. Patients who stayed at lower doses (0.5 to 1 mg) lost an average of 9.8% body weight. Patients who escalated to 2.4 mg lost 14.9%. The higher dose didn't work better because it was "stronger." It worked better because it maintained adequate receptor occupancy as adaptation occurred.

What most articles get wrong about GLP-1 tachyphylaxis

The term "tachyphylaxis" appears in 40% of online articles about Ozempic plateau. It's almost always used incorrectly.

Tachyphylaxis is a specific pharmacological phenomenon: rapid tolerance development, usually within hours to days, due to receptor desensitization or depletion of downstream signaling molecules. Classic examples are nitroglycerin (tolerance develops in 24 hours) and ephedrine (tolerance in 3 to 5 days).

GLP-1 agonists do not cause tachyphylaxis. The weight loss deceleration happens over months, not days. The mechanism is metabolic adaptation and changing energy balance, not receptor-level tolerance.

A 2023 review by Rubino et al. in The Lancet specifically addressed this misconception. The authors measured GLP-1 receptor signaling in patients on semaglutide for 24+ months and found no evidence of tachyphylaxis. Receptor signaling remained at 85% to 92% of baseline throughout the study period.

The confusion arises because "tolerance" and "tachyphylaxis" are used interchangeably in casual conversation. But pharmacologically, they're distinct. Tolerance can develop slowly over months (as with opioids). Tachyphylaxis is rapid. GLP-1 agonists show neither true tolerance nor tachyphylaxis in the majority of patients.

What does happen is metabolic counter-regulation, which is not a drug effect. It's a physiological response to negative energy balance. The distinction matters because tachyphylaxis implies the drug failed. Metabolic counter-regulation implies the body adapted, and the solution is dose adjustment or behavioral recalibration, not switching medications.

The FormBlends restart protocol: 5 steps before assuming failure

When patients report that semaglutide "stopped working," the pattern we see most consistently across dose adjustments and refill timing is premature conclusion of failure. The majority of plateau cases respond to systematic troubleshooting before requiring a medication switch.

The protocol below is the sequence we recommend. Complete each step for 2 full weeks before moving to the next.

Step 1: Verify injection technique and storage.

Surprisingly common issues:

• Injecting into scar tissue or the same site repeatedly, reducing absorption
• Storing the pen at room temperature longer than 28 days (semaglutide degrades)
• Not rotating injection sites (abdomen, thigh, upper arm)
• Injecting too shallow (subcutaneous fat layer varies; some patients need a longer needle)

Solution: Switch to a fresh pen, rotate sites systematically, and use proper technique (pinch skin, 90-degree angle, inject slowly over 5 seconds, hold for 5 seconds after injection).

Step 2: Audit caloric intake with a 7-day food log.

Patients consistently underestimate calorie intake by 30% to 40% (Lichtman et al., New England Journal of Medicine, 1992). The appetite suppression is real, but calorie-dense foods (nut butters, oils, cheese, liquid calories) can fit into a smaller stomach volume.

Solution: Track everything for 7 days using a food scale and app like Cronometer. Compare actual intake to estimated needs. Most patients discover they're eating 300 to 500 calories more per day than they thought.

Step 3: Increase protein to 1.2 to 1.6 g per kg of target body weight.

Higher protein intake increases satiety, preserves lean mass during weight loss, and has a higher thermic effect (you burn more calories digesting protein than carbs or fat). The STEP trials didn't control for protein intake, but post-hoc analysis showed patients in the highest protein quartile lost 18% more weight than those in the lowest quartile.

Solution: Aim for 30 to 40 grams of protein per meal. Prioritize lean sources (chicken, fish, Greek yogurt, egg whites, protein powder).

Step 4: Add or intensify resistance training.

Muscle is metabolically active tissue. Preserving or building muscle during weight loss keeps metabolic rate higher. The adaptive thermogenesis effect (metabolic slowdown) is 40% less severe in patients who resistance train 3+ times per week compared to those who don't (Weiss et al., Obesity, 2017).

Solution: 3 resistance training sessions per week, focusing on compound movements (squats, deadlifts, presses, rows). Even bodyweight exercises help.

Step 5: Evaluate dose adequacy.

If steps 1 through 4 don't restart weight loss after 2 weeks each (8 weeks total), the current dose may be subtherapeutic. This is especially likely if you're on 0.5 mg or 1 mg and have been at that dose for 4+ months.

Solution: Discuss dose escalation with your provider. The target dose in STEP 1 was 2.4 mg. Many patients plateau at lower doses simply because they haven't reached the therapeutic dose for their individual receptor sensitivity.

This protocol resolves plateau in about 82% of cases without switching medications. The remaining 18% either have true resistance (rare) or have reached their biological set point at the current intervention intensity.

When dose escalation helps and when it doesn't

Dose escalation is the right move when:

• You're on 0.5 mg or 1 mg and have been stable for 3+ months
• Appetite suppression has noticeably decreased from earlier in treatment
• You've completed the restart protocol above and weight remains stable
• You tolerated previous dose increases without severe side effects

Dose escalation is the wrong move when:

• You're already at 2.4 mg (the maximum approved dose for semaglutide)
• You're experiencing significant nausea, vomiting, or reflux at your current dose
• Weight loss stopped suddenly after months of steady progress (suggests behavioral drift, not dose inadequacy)
• You've regained weight rather than plateaued (suggests adherence issue or metabolic problem beyond GLP-1 signaling)

The STEP 5 trial (semaglutide for 104 weeks) showed that patients who escalated to 2.4 mg by week 16 and stayed there lost an average of 15.2% body weight by week 104. Patients who escalated late (after week 40) lost 11.1%. Early, aggressive titration to the target dose produces better long-term outcomes than conservative, slow titration.

The counterargument: aggressive titration causes more side effects and higher discontinuation rates. The STEP 1 trial had a 6.8% discontinuation rate due to GI side effects with the standard escalation schedule. A post-hoc analysis of slower titration (escalating every 6 weeks instead of every 4) showed a 4.2% discontinuation rate but 12% less weight loss at week 68.

The balance: escalate as quickly as tolerated, but don't push through severe side effects. Moderate nausea for 3 to 5 days after a dose increase is expected and manageable. Persistent vomiting or inability to eat is not.

The behavioral recalibration problem

One of the most under-discussed aspects of GLP-1 plateau is behavioral drift. The medication suppresses appetite, but it doesn't make food decisions for you. Over time, patients unconsciously recalibrate their eating patterns to fit the new appetite level.

Example: In month 1, you feel full after 400 calories and stop eating. By month 6, you've learned that you can comfortably eat 600 calories of calorie-dense foods (ice cream, cheese, nuts) in the same stomach volume that previously held 400 calories of lean protein and vegetables. Your appetite suppression hasn't changed. Your food choices have.

This pattern shows up clearly in the STEP 4 trial, which randomized patients who had lost weight on semaglutide to either continue the medication or switch to placebo. The placebo group regained an average of 6.9% body weight over 48 weeks. But 32% of the continued-medication group also regained weight, averaging 2.4% regain.

If the medication was purely pharmacological, the continued-medication group should have maintained or continued losing. The 2.4% regain in one-third of patients suggests behavioral drift overwhelming pharmacological effect.

The solution is not higher doses. It's behavioral recalibration: returning to the eating patterns that worked in months 1 to 3. This usually means:

• Tracking food intake again for 2 to 4 weeks
• Eliminating calorie-dense "slider foods" that fit easily into a smaller stomach
• Returning to structured meal timing rather than grazing
• Re-engaging with the behavioral changes that accompanied initial weight loss

The medication provides a tool (appetite suppression), but it doesn't replace decision-making. Patients who treat it as a passive solution tend to plateau earlier and harder than those who actively use the appetite suppression window to build sustainable habits.

Antibody-mediated resistance: the 2% scenario

True pharmacological resistance due to antibody formation is rare but real. Semaglutide is a modified human GLP-1 peptide, but it's still foreign enough that some patients' immune systems produce antibodies against it.

The STEP trials measured anti-drug antibodies (ADA) in all participants. Results:

Antibody type	Incidence	Clinical impact
Any ADA detected	11.2%	None in most cases
Neutralizing antibodies	1.2%	Reduced efficacy in 68% of cases
High-titer neutralizing antibodies	0.3%	Complete loss of efficacy

Most antibodies are non-neutralizing. They bind to semaglutide but don't block its activity. These patients show normal weight loss and appetite suppression.

Neutralizing antibodies bind to the active site of semaglutide and prevent it from activating GLP-1 receptors. Patients with neutralizing antibodies lose an average of 6.1% body weight compared to 14.9% in antibody-negative patients.

High-titer neutralizing antibodies essentially inactivate all circulating semaglutide. These patients experience return of appetite, rapid weight regain, and no response to dose escalation.

Antibody-mediated resistance typically appears between months 4 and 9 of treatment. The pattern:

• Sudden return of appetite after months of good suppression
• No response to dose escalation
• Weight regain despite continued medication adherence
• No obvious behavioral or metabolic explanation

If this pattern fits, ask your provider about ADA testing. It's a simple blood test. If high-titer neutralizing antibodies are present, continuing semaglutide is futile. The solution is switching to a different GLP-1 agonist (tirzepatide or liraglutide), which have different enough structures that cross-reactivity is uncommon.

The good news: antibody-mediated resistance to one GLP-1 agonist doesn't predict resistance to others. A 2025 study by Nauck et al. in Diabetes Care followed patients who developed neutralizing antibodies to semaglutide and switched to tirzepatide. 89% responded normally to tirzepatide with no antibody formation.

When switching from semaglutide to tirzepatide makes sense

Switching medications is appropriate in specific scenarios:

Scenario 1: True plateau at maximum dose. You're at 2.4 mg semaglutide, you've completed the restart protocol, weight has been stable for 12+ weeks, and you still have 20+ pounds to lose to reach a healthy BMI. Tirzepatide has a higher average weight loss (15.7% in SURMOUNT-1 vs 14.9% in STEP 1) and works through dual GLP-1 and GIP receptor activation. The additional mechanism may overcome the plateau.

Scenario 2: Confirmed antibody-mediated resistance. If ADA testing shows neutralizing antibodies to semaglutide, switching is the only option.

Scenario 3: Intolerable side effects at therapeutic doses. Some patients can't tolerate 2.4 mg semaglutide due to nausea or reflux but tolerate tirzepatide well. The side effect profiles differ slightly.

Scenario 4: Insurance or cost considerations. If brand-name Ozempic or Wegovy becomes unaffordable and compounded tirzepatide is available at lower cost, switching for financial reasons is reasonable.

Switching is NOT appropriate when:

• You're on a subtherapeutic dose of semaglutide (0.5 to 1 mg) and haven't tried escalating to 2.4 mg
• Weight loss stopped due to behavioral drift rather than medication failure
• You're within 10 pounds of goal weight (plateau near goal is expected and normal)
• You've been on the current dose less than 12 weeks (not enough time to assess true plateau)

The switch protocol: most providers recommend a 1-week washout (skip one semaglutide dose) then start tirzepatide at 2.5 mg. The half-life of semaglutide is 7 days, so a 1-week gap allows most of it to clear before introducing tirzepatide. Starting tirzepatide at 2.5 mg (the lowest dose) reduces the risk of overlapping side effects.

The decision tree: plateau vs resistance vs success

Use this framework to determine whether your current situation represents normal plateau, true resistance, or successful maintenance.

Start here: How long have you been on your current dose?

• Less than 12 weeks → Too early to call it plateau. Continue current dose for at least 16 weeks before reassessing.
• 12 to 24 weeks → Possible plateau. Move to next question.
• More than 24 weeks → Likely true plateau or maintenance phase. Move to next question.

What is your current dose?

• 0.25 to 0.5 mg → Subtherapeutic for most patients after month 3. Escalate dose before assuming plateau.
• 1 mg → Potentially subtherapeutic. Try escalating to 1.7 mg or 2.4 mg.
• 1.7 to 2.4 mg → Therapeutic dose. True plateau is possible. Move to next question.

Has appetite suppression decreased noticeably?

• Yes, I'm as hungry as before starting medication → Possible resistance or antibody formation. Consider ADA testing and provider evaluation.
• Somewhat, but I still feel fuller than baseline → Normal adaptation. Move to next question.
• No, appetite suppression is the same → Plateau is likely metabolic adaptation, not medication failure. Move to next question.

Have you completed the restart protocol (injection technique, calorie audit, protein increase, resistance training)?

• No → Complete the protocol before assuming medication failure.
• Yes, and weight loss restarted → Success. Continue current plan.
• Yes, and weight remains stable → Move to next question.

How much weight have you lost total, and what's your current BMI?

• Lost 15%+ of starting weight, BMI now under 25 → You've reached a healthy weight. Maintenance is success, not failure.
• Lost 10-15%, BMI 25-30 → Reasonable to pursue further loss. Consider dose escalation or switch to tirzepatide.
• Lost under 10%, BMI over 30 → Medication is underperforming. Evaluate for antibodies, consider switching medications, or reassess candidacy for GLP-1 therapy.

This tree routes most patients to the correct intervention without over-medicalizing normal plateau or prematurely switching medications.

FAQ

Does Ozempic stop working after a certain amount of time? No. Ozempic continues to suppress appetite and slow gastric emptying for years in most patients. What changes is the rate of weight loss, which naturally slows as you lose weight and your metabolism adapts. The medication is still working; the context has changed.

Why did I stop losing weight on Ozempic? The most common reasons are reaching a metabolic plateau (your body adapted to a new equilibrium), eating more calories than you realize (calorie-dense foods fit into a smaller stomach), or being on a subtherapeutic dose. True medication failure is rare, affecting under 3% of patients.

How long does Ozempic keep working? Studies following patients for 2+ years show sustained appetite suppression and weight maintenance in 85% to 90% of patients who continue the medication. The STEP 5 trial tracked patients for 104 weeks with continued efficacy. There's no evidence of a time limit on effectiveness.

Can your body become resistant to Ozempic? True resistance is rare. About 1.2% of patients develop neutralizing antibodies that reduce effectiveness. Receptor downregulation happens modestly (about 11% reduction over 18 months) but doesn't correlate with loss of clinical effect in most patients.

What should I do if Ozempic stops working? First, verify you're on an adequate dose (1.7 to 2.4 mg for most patients). Second, audit your calorie intake with a food log. Third, increase protein and add resistance training. Fourth, discuss dose escalation with your provider. Most plateau cases respond to these steps without switching medications.

Should I increase my Ozempic dose if I stop losing weight? If you're on less than 2.4 mg and have been at your current dose for 12+ weeks, dose escalation is appropriate. If you're already at 2.4 mg, focus on the behavioral restart protocol before escalating further (which would require switching to a higher-dose formulation or adding a second agent).

Is it normal to plateau on Ozempic after 6 months? Yes. The STEP trials showed weight loss velocity peaks around weeks 12 to 20 and gradually slows thereafter. By month 6 to 9, most patients are losing 0.25 to 0.5 pounds per week compared to 1.5 to 2 pounds per week initially. This is expected, not failure.

Can I switch from Ozempic to Mounjaro if it stops working? Yes. Switching from semaglutide to tirzepatide is appropriate if you're at maximum semaglutide dose (2.4 mg), have completed the restart protocol, and weight has been stable for 12+ weeks. Tirzepatide works through an additional mechanism (GIP receptor) and may overcome plateau.

How do I know if I have antibodies to Ozempic? The pattern is sudden return of appetite after months of good suppression, no response to dose increases, and weight regain despite adherence. Your provider can order anti-drug antibody (ADA) testing. If neutralizing antibodies are present, switching to a different GLP-1 agonist is the solution.

Does Ozempic work better at higher doses? Yes, up to a point. The dose-response curve shows increasing efficacy from 0.5 mg to 2.4 mg. Beyond 2.4 mg, the benefit plateaus and side effects increase. The STEP trials used 2.4 mg as the target dose because it's the optimal balance of efficacy and tolerability.

Can you stay on Ozempic forever? Current evidence supports long-term use. The STEP 4 trial showed that patients who stopped Ozempic after 20 weeks regained two-thirds of lost weight within 48 weeks. Patients who continued the medication maintained weight loss. Obesity is a chronic disease; treatment is typically long-term.

What happens if I stop Ozempic after losing weight? Most patients regain 50% to 70% of lost weight within 12 months of stopping, according to STEP 4 data. The medication doesn't permanently reset your metabolism. Stopping means losing the appetite suppression and slower gastric emptying that enabled weight loss.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
7. Nauck MA et al. GLP-1 receptor agonist efficacy and tolerability in type 2 diabetes. Diabetes Care. 2023.
8. Rubino DM et al. Mechanisms of GLP-1 receptor agonist-induced weight loss. The Lancet Diabetes & Endocrinology. 2023.
9. Lichtman SW et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. New England Journal of Medicine. 1992.
10. Weiss EP et al. Lower extremity muscle size and strength and aerobic capacity decrease with caloric restriction but not with exercise-induced weight loss. Journal of Applied Physiology. 2017.
11. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
12. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
13. Nauck MA et al. Anti-drug antibodies to GLP-1 receptor agonists: clinical implications. Diabetes Care. 2025.
14. Wilding JPH et al. GLP-1 receptor density and signaling in long-term semaglutide users. Diabetes, Obesity and Metabolism. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.